Epilepsy%20(pediatric) News

News

CBD yields comparable benefits in kids, adults with Lennox-Gastaut and Dravet syndrome

Jairia Dela Cruz, 20230517140000

Children with Lennox-Gastaut syndrome (LGS) and Dravet's syndrome (DS) achieve improvements in both seizure management and nonseizure outcomes following treatment with cannabidiol (CBD)—a success echoed in their adult counterparts, as shown in a study presented at AAN 2023.

Modified Atkins diet may be better than keto for childhood drug-resistant epilepsy

20230205150000

Dietary modifications offer short-term benefits in children with drug-resistant epilepsy, but modified Atkins diet appears more tolerable and more likely to reduce the frequency of seizures than ketogenic diet, as shown in a study.

Add-on cannabidiol induces sustained seizure reduction in treatment-resistant epilepsy

20230127100000

Patients with treatment-resistant epilepsy appear to benefit from add-on cannabidiol, which a recent study has shown to help reduce seizure frequency for up to 192 weeks.

Modified Atkins diet helps control drug-resistant epilepsy

Jairia Dela Cruz, 20230112090000

Teen and adult patients with drug-resistant epilepsy may benefit from modified Atkins diet, which has been shown in a recent study to produce improvements in seizure frequency, quality of life (QOL), and behavioural problems as compared with standard drug therapy.

Minimally invasive surgery safer but less effective than open surgery in children with DRE

20221207180000

In the treatment of children with drug-resistant epilepsy (DRE), minimally invasive magnetic resonance-guided laser interstitial thermal therapy is associated with lower rate of seizure freedom at 1 year but has the advantage of lower complication rates and shorter hospitalization as compared with open surgery, as shown in a study.

Sleep disturbance comes in three in kids with new-onset epilepsy

20221123080000

New research has shown that there are three distinct phenotypes of sleep disturbance in children with newly diagnosed epilepsy: minimal, moderate, and severe.

Cannabidivarin safe, reduces seizure frequency in paediatric MECP2-related Rett syndrome

20220601080000

Treatment with a nonhallucinogenic phytocannabinoid, cannabidivarin, is well tolerated in children with Rett syndrome (RTT), according to data from a phase 1 trial. Moreover, it improves seizure control in those whose disease is caused by methyl-CpG-binding protein 2 (MECP2) pathogenic variants.

Antiseizure effect of cannabidiol seen within 2 weeks of treatment

20220328060000

In the treatment of patients with drug-resistant epilepsy associated with tuberous sclerosis complex, the antiseizure effect of cannabidiol occurs within 6–10 days, according to the results of a phase III trial. Adverse events also emerge during the first 2 weeks of the titration period, and majority of these are resolved during the 16-week treatment period.

Intravenous brivaracetam safe in paediatric epilepsy

20220321080000

Treatment with intravenous brivaracetam is well tolerated in children with epilepsy, with a safety profile consistent with that known of the oral formulation, according to the results of a phase II study. There has been no pharmacokinetic difference observed when administered as bolus or a 15-minute infusion.

Original New Drug Application Approvals by US FDA (01-15 November 2021)

20211117081043

New drug applications approved by US FDA as of 01-15 November 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Product Highlight-Skycellflu

27 Sep 2018

SKYCELLFLU – Inactivated quadrivalent influenza vaccine (inj) 0.5 mL - AJ Biologics

Combined Ag/Ab rapid testing boosts case-finding in COVID-19

Elvira Manzano, 29 Jul 2021

A rapid and affordable test for diagnosing COVID-19 outside the walls of the healthcare units could improve case-finding, contact tracing, and infection control, says an expert during a pre-ECCMID 2021 session.

Gangliosides and cognition: An appraisal of the evidence

01 Sep 2018

Gangliosides and docosahexaenoic acid (DHA) play critical roles in early childhood brain development.